Enhanced endothelin-mediated coronary vasoconstriction and attenuated basal nitric oxide activity in experimental hypercholesterolemia.

BACKGROUND Experimental hypercholesterolemia is associated with coronary vasomotor dysfunction. This study was designed to test the hypothesis that experimental hypercholesterolemia is characterized by altered coronary vasomotor responses to endothelin and inhibition of the endogenous NO pathway. METHODS AND RESULTS Endothelin-1 (ET-1) at 5 ng x kg(-1) x min(-1) or N(G)-monomethyl-L-arginine (L-NMMA), a competitive inhibitor of nitric oxide synthase (NOS), at 50 microg x kg(-1) x min(-1) was infused into the left anterior descending coronary artery in pigs before and after 10 weeks of cholesterol diet. There was a significant increase in serum cholesterol. At 10 weeks, ET-1 resulted in an accentuated decrease in coronary blood flow (CBF) and coronary artery diameter (CAD) compared with baseline (-88+/-6% versus -45+/-9%, P<.05, and -77+/-14% versus -18+/-8%, P<.05, respectively) and an increase in coronary vascular resistance (CVR) (242+/-18% versus 110+/-17%, P<.05); ET receptor density and binding affinity in epicardial coronary arteries were unchanged. The effect of L-NMMA on CBF, CAD, and CVR was attenuated at 10 weeks (-7+/-8% versus -48+/-4%, -2+/-3% versus -17+/-5%, and 16+/-10% versus 125+/-32%; each P<.05). Immunohistochemistry staining for constitutive NOS revealed a decrease in immunoreactivity in the coronary arteries of hypercholesterolemic pigs. CONCLUSIONS The present study demonstrates an enhanced coronary vasoconstrictive response to pathophysiological doses of endothelin and an attenuated response to the inhibition of endogenous NO activity, suggesting an alteration in coronary vascular reactivity in experimental hypercholesterolemia.

[1]  A. Lerman,et al.  The role of endothelin in coronary atherosclerosis. , 1996, Mayo Clinic proceedings.

[2]  E. Schiffrin,et al.  Vascular structure and expression of endothelin-1 gene in L-NAME-treated spontaneously hypertensive rats. , 1996, Hypertension.

[3]  M. Turina,et al.  Up-regulation of endothelin-B receptors in atherosclerotic human coronary arteries. , 1996, Journal of cardiovascular pharmacology.

[4]  Y. Wang,et al.  Reciprocal regulation of endothelin-1 and endothelial constitutive NOS in proliferating endothelial cells. , 1995, The American journal of physiology.

[5]  A. Lerman,et al.  Endothelin at pathophysiological concentrations mediates coronary vasoconstriction via the endothelin-A receptor. , 1995, Circulation.

[6]  M. Mohaupt,et al.  Endothelin-1 inhibits cytokine-stimulated transcription of inducible nitric oxide synthase in glomerular mesangial cells. , 1995, Kidney international.

[7]  M. Bell,et al.  Endothelin in coronary endothelial dysfunction and early atherosclerosis in humans. , 1995, Circulation.

[8]  V. Fuster,et al.  Circulating and Tissue Endothelin Immunoreactivit in Hypercholesterolemic Pigs , 1993, Circulation.

[9]  J. Rouleau,et al.  Regulation of the endothelin-1 transmembrane signaling pathway: the potential role of agonist-induced desensitization in the coronary artery of the rapid ventricular pacing-overdrive dog model of heart failure. , 1993, Journal of molecular and cellular cardiology.

[10]  M. Kern,et al.  Coronary flow velocity dynamics in normal and diseased arteries. , 1993, The American journal of cardiology.

[11]  D. Bergsma,et al.  Molecular characterization and regulation of the human endothelin receptors. , 1993, The Journal of biological chemistry.

[12]  G. Bilder,et al.  Modulation of vascular reactivity by vasoactive peptides in aortic rings from hypercholesterolemic rabbits. , 1992, European journal of pharmacology.

[13]  J. Cooke,et al.  L-arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans. , 1992, The Journal of clinical investigation.

[14]  P. Tsao,et al.  Antiatherogenic effects of L-arginine in the hypercholesterolemic rabbit. , 1992, The Journal of clinical investigation.

[15]  T. Lüscher,et al.  Oxidized low density lipoproteins induce mRNA expression and release of endothelin from human and porcine endothelium. , 1992, Circulation research.

[16]  S. Moncada,et al.  Role of nitric oxide synthesis in the regulation of coronary vascular tone in the isolated perfused rabbit heart. , 1992, Cardiovascular research.

[17]  A. Lerman,et al.  Inhibition of Endothelium‐Derived Relaxing Factor Enhances Endothelin‐Mediated Vasoconstriction , 1992, Circulation.

[18]  H. M. Payne,et al.  Validation of A Doppler Guide Wire for Intravascular Measurement of Coronary Artery Flow Velocity , 1992, Circulation.

[19]  P. Ganz,et al.  Patients With Evidence of Coronary Endothelial Dysfunction as Assessed by Acetylcholine Infusion Demonstrate Marked Increase in Sensitivit to Constrictor Effects of Catecholamines , 1992, Circulation.

[20]  T. Lüscher,et al.  Endothelin stimulated by angiotensin II augments contractility of spontaneously hypertensive rat resistance arteries. , 1992, Hypertension.

[21]  V. Fuster,et al.  The pathogenesis of coronary artery disease and the acute coronary syndromes (2). , 1992, The New England journal of medicine.

[22]  H. Drexler,et al.  Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolaemic patients by L-arginine , 1991, The Lancet.

[23]  J. Fruchart,et al.  Modified low density lipoproteins activate human macrophages to secrete immunoreactive endothelin , 1991, FEBS letters.

[24]  A. Lerman,et al.  Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. , 1991, The New England journal of medicine.

[25]  T. Horio,et al.  Increased plasma immunoreactive endothelin-1 concentration in hypercholesterolemic rats. , 1991, Atherosclerosis.

[26]  T. Lüscher,et al.  Oxidized low density lipoproteins inhibit relaxations of porcine coronary arteries. Role of scavenger receptor and endothelium-derived nitric oxide. , 1991, Circulation.

[27]  J. Cooke,et al.  Arginine Restores Cholinergic Relaxation of Hypercholesterolemic Rabbit Thoracic Aorta , 1991, Circulation.

[28]  H. Drexler,et al.  Modulation of coronary vasomotor tone in humans. Progressive endothelial dysfunction with different early stages of coronary atherosclerosis. , 1991, Circulation.

[29]  R Busse,et al.  Effects of native and oxidized low density lipoproteins on formation and inactivation of endothelium-derived relaxing factor. , 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.

[30]  K. Margulies,et al.  Endothelin: a new cardiovascular regulatory peptide. , 1990, Mayo Clinic proceedings.

[31]  M. Yacoub,et al.  Low basal and stimulated release of nitric oxide in atherosclerotic epicardial coronary arteries , 1990, The Lancet.

[32]  S. Moncada,et al.  A specific inhibitor of nitric oxide formation from l‐arginine attenuates endothelium‐dependent relaxation , 1989, British journal of pharmacology.

[33]  S. Moncada,et al.  Vascular endothelial cells synthesize nitric oxide from L-arginine , 1988, Nature.

[34]  Sadao Kimura,et al.  A novel potent vasoconstrictor peptide produced by vascular endothelial cells , 1988, Nature.

[35]  D. Holmes,et al.  Estimation of the effects of angioplasty on coronary stenosis using quantitative video angiography. , 1985, Catheterization and cardiovascular diagnosis.